Cochrane · systematic review · CD010891
Genetic testing for prevention of severe drug‐induced skin rash
Alfirevic, A, Pirmohamed, M, Marinovic, B, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
2
No studies
6
Included studies
NR
No studies 6 · 75%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 25%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen containing abacavir but with an unknown HLA‐B*57:01 status.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Severe skin drug‐induced rash | no estimate extracted | NR | No studies |
Long‐term sequelae | no estimate extracted | NR | No studies |
Hospitalisation for drug‐induced skin reaction | no estimate extracted | NR | No studies |
SJS/TEN (Stevens‐Johnson syndrome/toxic epidermal necrolysis) | no estimate extracted | NR | No studies |
AGEP (acute generalised exanthematous pustulosis) | no estimate extracted | NR | No studies |
HSS (hypersensitivity) reaction including SJS/TEN (clinically diagnosed) (6 weeks clinical assessment) | RR 0.43 [0.28, 0.67] | 1 study · 1650 participants | Moderate Downgraded: risk of bias |
HSS reaction including SJS/TEN (immunologically confirmed) (6 weeks clinical assessment) | RR 0.02 [0, 0.37] | 1 study · 1644 participants | Moderate Downgraded: risk of bias |
Death | no estimate extracted | NR | No studies |